Skip to contentA
Alnylam Pharmaceuticals, Inc.
A
ALNYAlnylam Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$125.85M$125.85M+79.6% vs Q3 2019 Net Income-$253.29M-$253.29MN/M vs Q3 2019 EPS Diluted-$2.18-$2.18N/M vs Q3 2019 Operating Income-$225,199,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$122,744,000N/M Margins · derivedOperating margin-178.9%+129.8 pt vs Q3 2019
Net margin-201.3%+96.4 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end